A Study of RO4607381 in Patients With Coronary Heart Disease (CHD) or a CHD Risk Equivalent.
This study has been completed.
Sponsor:
Hoffmann-La Roche
Information provided by (Responsible Party):
Hoffmann-La Roche
ClinicalTrials.gov Identifier:
NCT00353522
First received: July 17, 2006
Last updated: September 14, 2012
Last verified: September 2012
Tracking Information | |||||
---|---|---|---|---|---|
First Received Date ICMJE | July 17, 2006 | ||||
Last Updated Date | September 14, 2012 | ||||
Start Date ICMJE | July 2006 | ||||
Primary Completion Date | October 2008 (final data collection date for primary outcome measure) | ||||
Current Primary Outcome Measures ICMJE |
Percentage and absolute change from baseline in HDL-C [ Time Frame: Week 24 ] [ Designated as safety issue: No ] | ||||
Original Primary Outcome Measures ICMJE |
Percentage and absolute change from baseline to week 24 in HDL-C level. | ||||
Change History | Complete list of historical versions of study NCT00353522 on ClinicalTrials.gov Archive Site | ||||
Current Secondary Outcome Measures ICMJE |
|
||||
Original Secondary Outcome Measures ICMJE |
Efficacy: Change from baseline in TC, TG, HDL-C, LDL-C, CETP mass and activity, ApoAI, ApOB. Safety: AEs, laboratory parameters. Change in mesenteric lymph nodes. | ||||
Current Other Outcome Measures ICMJE | |||||
Original Other Outcome Measures ICMJE | |||||
Descriptive Information | |||||
Brief Title ICMJE | A Study of RO4607381 in Patients With Coronary Heart Disease (CHD) or a CHD Risk Equivalent. | ||||
Official Title ICMJE | A Phase II, Double-Blind, Randomized, Placebo-controlled, Parallel Group Study, Evaluating the Efficacy and Safety of RO4607381 Over a 24-week Period in Patients With CHD or a CHD Risk Equivalent | ||||
Brief Summary | This 2 arm study will investigate the efficacy and safety of RO4607381 in patients with coronary heart disease, or CHD risk equivalent. After a pre-randomization phase of 5-12 weeks, patients will be randomized to receive either RO4607381 (900mg po) or placebo po daily for 24 weeks, with concomitant atorvastatin 10-80mg daily, and changes in cholesterol level and lipoprotein metabolism will be measured. The anticipated time on study treatment is 3-12 months, and the target sample size is 100-500 individuals. |
||||
Detailed Description | |||||
Study Type ICMJE | Interventional | ||||
Study Phase | Phase 2 | ||||
Study Design ICMJE | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Investigator) Primary Purpose: Treatment |
||||
Condition ICMJE | Coronary Heart Disease | ||||
Intervention ICMJE |
|
||||
Study Arm (s) |
|
||||
Publications * | |||||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. |
|||||
Recruitment Information | |||||
Recruitment Status ICMJE | Completed | ||||
Enrollment ICMJE | 135 | ||||
Completion Date | October 2008 | ||||
Primary Completion Date | October 2008 (final data collection date for primary outcome measure) | ||||
Eligibility Criteria ICMJE | Inclusion Criteria:
Exclusion Criteria:
|
||||
Gender | Both | ||||
Ages | 18 Years to 75 Years | ||||
Accepts Healthy Volunteers | No | ||||
Contacts ICMJE | Contact information is only displayed when the study is recruiting subjects | ||||
Location Countries ICMJE | United States, Germany | ||||
Administrative Information | |||||
NCT Number ICMJE | NCT00353522 | ||||
Other Study ID Numbers ICMJE | NC19453 | ||||
Has Data Monitoring Committee | |||||
Responsible Party | Hoffmann-La Roche | ||||
Study Sponsor ICMJE | Hoffmann-La Roche | ||||
Collaborators ICMJE | |||||
Investigators ICMJE |
|
||||
Information Provided By | Hoffmann-La Roche | ||||
Verification Date | September 2012 | ||||
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |